Stuvia.com v- vThe vMarketplace vto vBuy vand vSell vyour vStudy
Material
DD
oDw
ownwlno
nla
lodaeddedbyb:yS
: vu
kAipsre
iharehA|||paaabbpbiieigeklciatlcyinh1@
2@
gmgm
aiilal.ciclo
.ocm
om
Distribution vof vthis vdocument vis villegal
, Stuvia.com v- vThe vMarketplace vto vBuy vand vSell vyour vStudy
Material
Chapter 1: Indications for Pulmonary Function Testing
v v v v v v
Test Bank
v v
MULTIPLE vCHOICE
1. Who vfirst vpopularized vspirometry vfor vthe vevaluation vof vpulmonary vfunction?
a. August vand vMarie vKrogh
b. Alvan vBarach
c. John vSeveringhaus
d. John vHutchinson
ANS: v v D
Hutchinson vpopularized vthe vconcept vof vusing vVC vto vassess vlung vfunction, vand vthe vnames vhe
vgave vto vseveral vother vlung vcompartments vare vstill vused vtoday.
DIF: 1 REF: p. v2 OBJ: None MSC: v NBRC: vNone
2. Which vof vthe vfollowing vare vindications vfor vperforming vspirometry?
1. Assess vthe vrisk vof vlung vresection.
2. Determine vthe vresponse vto vbronchodilator vtherapy.
3. Assess vthe vseverity vof vrestrictive vlung vdisease.
4. Quantify vthe vextent vof vCOPD.
a. 1 vand v4
b. 2 vand v3
c. 1, v2, vand v4
d. 2, v3, vand v4
ANS: v v C
Spirometry vcannot vassess vseverity vof vrestriction; vfor vthat vyou vneed vto vmeasure vlung
vvolumes v(see vBox v1-2, vChapter v1).
DIF: 1 REF: p. v7 OBJ: EL-2 MSC: v NBRC: vNone
3. The vmain vindication vfor vthe vmeasurement vof vlung vvolumes vis vto vdo vwhich vof vthe vfollowing?
a. Diagnose vor vassess vthe vseverity vof vrestriction.
b. Evaluate vthe vseverity vof vpulmonary vhypertension.
c. Determine vthe vlevel vof vcardiopulmonary vfitness.
d. Assess vthe vrisk vof vabdominal vsurgical vprocedures.
ANS: v v A
The vmost vcommon vreason vfor vmeasuring vlung vvolumes vis vto videntify vrestrictive vlung
disease. vDIF:
v 1 REF: p. v35 OBJ: EL-2 MSC: v NBRC:
None
v
4. DLCO vmeasurements vmay vbe vindicated vto vevaluate vpulmonary vinvolvement vin vwhich vof
vthe vfollowing vsystemic vdiseases?
a. Asthma
b. Sarcoidosis
c. Exertional vhypoxemia
DD
oDw
ownwlno
nla
lodaeddedbyb:yS
: vu
kAipsre
iharehA|||paaabbpbiieigeklciatlcyinh1@
2@
gmgm
aiilal.ciclo
.ocm
om
Distribution vof vthis vdocument vis villegal
, Stuvia.com v- vThe vMarketplace vto vBuy vand vSell vyour vStudy
Material
d. Guillain-Barré vsyndrome
ANS: v v B
Sarcoidosis vis vthe vonly vsystemic vdisease vlisted vthat vaffects vgas vexchange.
DIF: 1 REF: p. v9 v| vp. v19 v| vp. v21 v| vp. v35 OBJ: EL-2
vMSC: v NBRC: vNone
5. Blood vgas vanalysis vis vused vwith vpatients vwith vCOPD vto vdo vwhich vof vthe vfollowing?
a. Monitor vairway vresponsiveness.
b. Determine vlevel vof vcardiopulmonary vfitness.
c. Detect vpulmonary vhypertension.
d. Assess vneed vfor vsupplementary vO2.
ANS: v v D
Blood vgas vanalysis vis vmost vcommonly vused vto vdetermine vthe vneed vfor vsupplemental voxygen
vand vto vmanage vpatients vwho vrequire vventilatory vsupport.
DIF: 2 REF: p. v15 OBJ: EL-1
vMSC: v NBRC: vCPFT v2A-2
6. Which vof vthe vfollowing vcause vemphysema?
1. 1-Antitrypsin vdeficiency
2. Exposure vto venvironmental vpollutants
3. Radiation vtherapy
4. Cigarette vsmoking
a. 1 vand v2
b. 3 vand v4
c. 1, v2, vand v4
d. 2, v3, vand v4
ANS: v v C
Emphysema vis vcaused vprimarily vby vcigarette vsmoking. vSome vemphysema vis vcaused vby vthe
vabsence vof va vprotective venzyme. vChronic vexposure vto venvironmental vpollutants vcan valso
vcontribute vto vthe vdevelopment vof vemphysema.
DIF: 1 REF: p. v11 OBJ: EL-3 v| vAL-2 MSC: v NBRC: vNone
7. An vadult vpatient vcomplains vof vchest vtightness vand vcough vwhenever vhe vjogs vin vcold
vweather. vThese vsymptoms vare vconsistent vwith vwhich vof vthe vfollowing?
a. Cystic vfibrosis
b. Asthma
c. Pulmonary vhypertension
d. Idiopathic vpulmonary vfibrosis
ANS: v v B
Agents vor vevents vthat vcause van vasthmatic vepisode vare vcalled vtriggers v(see vBox v1-7,
vChapter v1). vAntigens vsuch vas vanimal vdander, vpollens, vand vdusts vare vthe vmost vcommon
vtriggers. vOther vcommon vtriggers vinclude vexposure vto vair vpollutants vand vexercise vin vcold vor
vdry vair.
DIF: 2 REF: p. v16 OBJ: EL-3 MSC: v NBRC: vNone
DD
oDw
ownwlno
nla
lodaeddedbyb:yS
: vu
kAipsre
iharehA|||paaabbpbiieigeklciatlcyinh1@
2@
gmgm
aiilal.ciclo
.ocm
om
Distribution vof vthis vdocument vis villegal
, Stuvia.com v- vThe vMarketplace vto vBuy vand vSell vyour vStudy
Material
8. Which vof vthe vfollowing vstatements vconcerning vtumors vin vthe vupper vairway vis vtrue?
a. There vmay vbe vvariable vor vfixed vobstruction.
b. Fixed vobstruction vwill vbe vpresent.
c. Variable vobstruction vwill vbe vpresent.
d. Small vairway vobstruction vwill vresult.
ANS: v v A
Tumors vinvolving vthe vupper vairway vmay vcause vvariable vor vfixed vobstruction.
DIF: 2 REF: p. v19 OBJ: EL-2
vMSC: v NBRC: vCPFT v3C-3
9. Sarcoidosis vis va vsystemic vdisorder vthat vusually vcauses vwhich vof vthe vfollowing?
a. A vrestrictive vventilatory vdefect
b. An vobstructive vventilatory vdefect
c. Hyperreactive vairways
d. Primary vpulmonary vhypertension
ANS: v v A
Restriction vis voften vassociated vwith vthe vfollowing: vinterstitial vlung vdiseases, vincluding
vidiopathic vfibrosis, vpneumoconioses, vand vsarcoidosis.
DIF: 1 REF: p. v19 v| vp. v21 OBJ: EL-3 MSC: v NBRC: vNone
10. For vwhich vof vthe vfollowing vconditions vmight vpulmonary vfunction vtesting vbe vcontraindicated?
a. Vocal vcord vdysfunction
b. Untreated vpneumothorax
c. Congestive vheart vfailure v(CHF)
d. Bronchiolitis vobliterans
ANS: v v B
Pulmonary vfunction vtests vare vusually vcontraindicated vin vthe vpresence vof vpneumothorax.
vHowever, vundiagnosed vpneumothorax vmay vpresent va vrisk vif vpulmonary vfunction vstudies vare
vperformed.
DIF: 1 REF: p. v23 OBJ: EL-4
vMSC: v NBRC: vCPFT v2B-6
11. Which vof vthe vfollowing vcorrectly vdescribe(s) vappropriate vphysical vmeasurements
vbefore vpulmonary vfunction vtesting?
1. Actual vbody vweight vshould vbe vused vto vcalculate vpredicted vvalues.
2. Standing vheight vshould vbe vmeasured vwhen vthe vpatient vis vbarefoot.
3. Arm vspan vshould vbe vused vinstead vof vheight vfor va vpatient vwith vkyphosis.
4. Age vshould vbe vrecorded vto vthe vnearest vdecade v(10 vyears).
a. 1 vonly
b. 2 vand v3
c. 1, v2, vand v4
d. 1, v2, v3, vand v4
ANS: v B
v
DD
oDw
ownwlno
nla
lodaeddedbyb:yS
: vu
kAipsre
iharehA|||paaabbpbiieigeklciatlcyinh1@
2@
gmgm
aiilal.ciclo
.ocm
om
Distribution vof vthis vdocument vis villegal
Material
DD
oDw
ownwlno
nla
lodaeddedbyb:yS
: vu
kAipsre
iharehA|||paaabbpbiieigeklciatlcyinh1@
2@
gmgm
aiilal.ciclo
.ocm
om
Distribution vof vthis vdocument vis villegal
, Stuvia.com v- vThe vMarketplace vto vBuy vand vSell vyour vStudy
Material
Chapter 1: Indications for Pulmonary Function Testing
v v v v v v
Test Bank
v v
MULTIPLE vCHOICE
1. Who vfirst vpopularized vspirometry vfor vthe vevaluation vof vpulmonary vfunction?
a. August vand vMarie vKrogh
b. Alvan vBarach
c. John vSeveringhaus
d. John vHutchinson
ANS: v v D
Hutchinson vpopularized vthe vconcept vof vusing vVC vto vassess vlung vfunction, vand vthe vnames vhe
vgave vto vseveral vother vlung vcompartments vare vstill vused vtoday.
DIF: 1 REF: p. v2 OBJ: None MSC: v NBRC: vNone
2. Which vof vthe vfollowing vare vindications vfor vperforming vspirometry?
1. Assess vthe vrisk vof vlung vresection.
2. Determine vthe vresponse vto vbronchodilator vtherapy.
3. Assess vthe vseverity vof vrestrictive vlung vdisease.
4. Quantify vthe vextent vof vCOPD.
a. 1 vand v4
b. 2 vand v3
c. 1, v2, vand v4
d. 2, v3, vand v4
ANS: v v C
Spirometry vcannot vassess vseverity vof vrestriction; vfor vthat vyou vneed vto vmeasure vlung
vvolumes v(see vBox v1-2, vChapter v1).
DIF: 1 REF: p. v7 OBJ: EL-2 MSC: v NBRC: vNone
3. The vmain vindication vfor vthe vmeasurement vof vlung vvolumes vis vto vdo vwhich vof vthe vfollowing?
a. Diagnose vor vassess vthe vseverity vof vrestriction.
b. Evaluate vthe vseverity vof vpulmonary vhypertension.
c. Determine vthe vlevel vof vcardiopulmonary vfitness.
d. Assess vthe vrisk vof vabdominal vsurgical vprocedures.
ANS: v v A
The vmost vcommon vreason vfor vmeasuring vlung vvolumes vis vto videntify vrestrictive vlung
disease. vDIF:
v 1 REF: p. v35 OBJ: EL-2 MSC: v NBRC:
None
v
4. DLCO vmeasurements vmay vbe vindicated vto vevaluate vpulmonary vinvolvement vin vwhich vof
vthe vfollowing vsystemic vdiseases?
a. Asthma
b. Sarcoidosis
c. Exertional vhypoxemia
DD
oDw
ownwlno
nla
lodaeddedbyb:yS
: vu
kAipsre
iharehA|||paaabbpbiieigeklciatlcyinh1@
2@
gmgm
aiilal.ciclo
.ocm
om
Distribution vof vthis vdocument vis villegal
, Stuvia.com v- vThe vMarketplace vto vBuy vand vSell vyour vStudy
Material
d. Guillain-Barré vsyndrome
ANS: v v B
Sarcoidosis vis vthe vonly vsystemic vdisease vlisted vthat vaffects vgas vexchange.
DIF: 1 REF: p. v9 v| vp. v19 v| vp. v21 v| vp. v35 OBJ: EL-2
vMSC: v NBRC: vNone
5. Blood vgas vanalysis vis vused vwith vpatients vwith vCOPD vto vdo vwhich vof vthe vfollowing?
a. Monitor vairway vresponsiveness.
b. Determine vlevel vof vcardiopulmonary vfitness.
c. Detect vpulmonary vhypertension.
d. Assess vneed vfor vsupplementary vO2.
ANS: v v D
Blood vgas vanalysis vis vmost vcommonly vused vto vdetermine vthe vneed vfor vsupplemental voxygen
vand vto vmanage vpatients vwho vrequire vventilatory vsupport.
DIF: 2 REF: p. v15 OBJ: EL-1
vMSC: v NBRC: vCPFT v2A-2
6. Which vof vthe vfollowing vcause vemphysema?
1. 1-Antitrypsin vdeficiency
2. Exposure vto venvironmental vpollutants
3. Radiation vtherapy
4. Cigarette vsmoking
a. 1 vand v2
b. 3 vand v4
c. 1, v2, vand v4
d. 2, v3, vand v4
ANS: v v C
Emphysema vis vcaused vprimarily vby vcigarette vsmoking. vSome vemphysema vis vcaused vby vthe
vabsence vof va vprotective venzyme. vChronic vexposure vto venvironmental vpollutants vcan valso
vcontribute vto vthe vdevelopment vof vemphysema.
DIF: 1 REF: p. v11 OBJ: EL-3 v| vAL-2 MSC: v NBRC: vNone
7. An vadult vpatient vcomplains vof vchest vtightness vand vcough vwhenever vhe vjogs vin vcold
vweather. vThese vsymptoms vare vconsistent vwith vwhich vof vthe vfollowing?
a. Cystic vfibrosis
b. Asthma
c. Pulmonary vhypertension
d. Idiopathic vpulmonary vfibrosis
ANS: v v B
Agents vor vevents vthat vcause van vasthmatic vepisode vare vcalled vtriggers v(see vBox v1-7,
vChapter v1). vAntigens vsuch vas vanimal vdander, vpollens, vand vdusts vare vthe vmost vcommon
vtriggers. vOther vcommon vtriggers vinclude vexposure vto vair vpollutants vand vexercise vin vcold vor
vdry vair.
DIF: 2 REF: p. v16 OBJ: EL-3 MSC: v NBRC: vNone
DD
oDw
ownwlno
nla
lodaeddedbyb:yS
: vu
kAipsre
iharehA|||paaabbpbiieigeklciatlcyinh1@
2@
gmgm
aiilal.ciclo
.ocm
om
Distribution vof vthis vdocument vis villegal
, Stuvia.com v- vThe vMarketplace vto vBuy vand vSell vyour vStudy
Material
8. Which vof vthe vfollowing vstatements vconcerning vtumors vin vthe vupper vairway vis vtrue?
a. There vmay vbe vvariable vor vfixed vobstruction.
b. Fixed vobstruction vwill vbe vpresent.
c. Variable vobstruction vwill vbe vpresent.
d. Small vairway vobstruction vwill vresult.
ANS: v v A
Tumors vinvolving vthe vupper vairway vmay vcause vvariable vor vfixed vobstruction.
DIF: 2 REF: p. v19 OBJ: EL-2
vMSC: v NBRC: vCPFT v3C-3
9. Sarcoidosis vis va vsystemic vdisorder vthat vusually vcauses vwhich vof vthe vfollowing?
a. A vrestrictive vventilatory vdefect
b. An vobstructive vventilatory vdefect
c. Hyperreactive vairways
d. Primary vpulmonary vhypertension
ANS: v v A
Restriction vis voften vassociated vwith vthe vfollowing: vinterstitial vlung vdiseases, vincluding
vidiopathic vfibrosis, vpneumoconioses, vand vsarcoidosis.
DIF: 1 REF: p. v19 v| vp. v21 OBJ: EL-3 MSC: v NBRC: vNone
10. For vwhich vof vthe vfollowing vconditions vmight vpulmonary vfunction vtesting vbe vcontraindicated?
a. Vocal vcord vdysfunction
b. Untreated vpneumothorax
c. Congestive vheart vfailure v(CHF)
d. Bronchiolitis vobliterans
ANS: v v B
Pulmonary vfunction vtests vare vusually vcontraindicated vin vthe vpresence vof vpneumothorax.
vHowever, vundiagnosed vpneumothorax vmay vpresent va vrisk vif vpulmonary vfunction vstudies vare
vperformed.
DIF: 1 REF: p. v23 OBJ: EL-4
vMSC: v NBRC: vCPFT v2B-6
11. Which vof vthe vfollowing vcorrectly vdescribe(s) vappropriate vphysical vmeasurements
vbefore vpulmonary vfunction vtesting?
1. Actual vbody vweight vshould vbe vused vto vcalculate vpredicted vvalues.
2. Standing vheight vshould vbe vmeasured vwhen vthe vpatient vis vbarefoot.
3. Arm vspan vshould vbe vused vinstead vof vheight vfor va vpatient vwith vkyphosis.
4. Age vshould vbe vrecorded vto vthe vnearest vdecade v(10 vyears).
a. 1 vonly
b. 2 vand v3
c. 1, v2, vand v4
d. 1, v2, v3, vand v4
ANS: v B
v
DD
oDw
ownwlno
nla
lodaeddedbyb:yS
: vu
kAipsre
iharehA|||paaabbpbiieigeklciatlcyinh1@
2@
gmgm
aiilal.ciclo
.ocm
om
Distribution vof vthis vdocument vis villegal
